

Life Sciences & Materials Sciences

Staying the Course

Rolf-Dieter Schwalb
CFO Royal DSM



Nomura Global Chemicals Industry Leaders Conference
Edinburgh Thursday 26 March 2009

Safe Harbor Statement

This presentation may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this presentation, unless required by law.

The English language version of this document is leading.

A more comprehensive discussion of the risk factors affecting DSM's business can be found in the company's latest Annual Report, which can be found on the company's corporate website, www.dsm.com

Agenda

- Operational performance 2008
- *Vision 2010* update
- Outlook 2009

Highlights 2008

DSM reports record year despite global economic downturn in Q4

- Full year operating profit up 10% to EUR 903 million; Q4 down 35% to EUR 123 million
- Continuing strong performance from Life Sciences businesses and DSM Dyneema in Q4
- Most Materials Sciences businesses severely impacted by downturn since beginning of Q4
- Focus on cash over profitability generates strong cash flow in Q4; cost saving program of EUR 100 million under way
- Solid long-term financial position; dividend maintained at EUR 1.20 per share
- No quantitative outlook provided for 2009 in view of the uncertain economic conditions

Annual Results 2008: key figures

Q4'08	Q4'07	Δ%	(€ million)	2008	2007	Δ%
			<u>before exceptional:</u>			
2,091	2,226	- 6%	Net Sales	9,297	8,757	+ 6%
241	300	-20%	EBITDA	1,357	1,247	+ 9%
123	190	-35%	EBIT	903	823	+10%
73	130	-44%	Net Profit	608	558	+ 9%
0.43	0.75	-43%	EPS	3.64	3.07	+19%
			<u>including exceptional items:</u>			
42	112	-62%	Net Profit	577	429	+34%
0.24	0.64	-63%	EPS	3.45	2.35	+47%

Net sales growth Q4'2008 versus Q4'2007

(€ million)	Q4'08	Q4'07	Difference	Volume	Price	FX	Other
Nutrition	703	600	17%	-7%	19%	5%	0%
Pharma	216	234	-8%	2%	-5%	1%	-6%
Performance Materials	492	598	-18%	-20%	-2%	3%	1%
Polymer Intermediates	198	323	-39%	-41%	-6%	8%	0%
Base Chemicals & Materials	353	389	-9%	-33%	21%	2%	1%
Other activities	129	82					
Total continuing operations	2,091	2,226	-6%	-18%	8%	4%	0%

Net sales growth FY 2008 versus FY 2007

(€ million)	2008	2007	Difference	Volume	Price	FX	Other
Nutrition	2,710	2,302	18%	2%	19%	-4%	1%
Pharma	863	903	-4%	0%	0%	-3%	-1%
Performance Materials	2,297	2,390	-4%	-4%	1%	-2%	1%
Polymer Intermediates	1,201	1,232	-3%	-6%	6%	-3%	0%
Base Chemicals & Materials	1,733	1,529	13%	-10%	24%	-1%	0%
Other activities	493	401					
Total continuing operations	9,297	8,757	6%	-3%	11%	-3%	1%

Nutrition

Q4'08	Q4'07	Δ%	(€ million)	2008	2007	Δ%
703	600	+ 17%	Net sales	2,710	2,302	+18%
189	105	+ 80%	EBITDA	585	403	+45%
155	72	+115%	EBIT	447	276	+62%
26.9%	17.5%		EBITDA margin	21.6%	17.5%	

- DNP benefiting from differentiation and innovation strategy in vitamins and changing industry dynamics
- DFS results affected by marginal sales decline and lower US\$
- Ongoing favorable business conditions

Pharma

Q4'08	Q4'07	Δ%	(€ million)	2008	2007	Δ%
216	234	- 8%	Net sales	863	903	- 4%
45	33	+36%	EBITDA	150	168	-11%
30	19	+58%	EBIT	89	92	- 3%
20.8%	14.1%		EBITDA margin	17.4%	18.6%	

- DPP impacted by Roche contracts, insourcing and delays in commercial developments
- DAI stays at a healthy level. PEN prices on average lower, but still at a good level

Performance Materials

Q4'08	Q4'07	Δ%	(€ million)	2008	2007	Δ%
492	598	- 18%	Net sales	2,297	2,390	- 4%
-9	91		EBITDA	266	371	-28%
-37	70		EBIT	175	291	-40%
-1.8%	15.2%		EBITDA margin	11.6%	15.5%	

- DEP as well as DR seriously hit by the economic crisis in Q4
- Combined effect of a sharp drop in demand, destocking, lower margins and inventory write-offs
- DSM Dyneema and parts of DR (Desotech) not affected by the crisis

Polymer Intermediates

Q4'08	Q4'07	Δ%	(€ million)	2008	2007	Δ%
198	323	- 39%	Net sales	1,201	1,232	- 3%
-62	42		EBITDA	43	133	-68%
-66	32		EBIT	19	105	-82%
-31.3%	13.0%		EBITDA margin	3.6%	10.8%	

- Severe drop in demand in all regions in Q4 (including China)
- Sudden and deep drop in benzene prices had very adverse inventory valuation effect
- Caprolactam earlier in the cycle than ACN

Base Chemicals and Materials

Q4'08	Q4'07	Δ%	(€ million)	2008	2007	Δ%
353	389	- 9%	Net sales	1,733	1,529	+13%
66	40	+ 65%	EBITDA	342	209	+64%
44	22	+100%	EBIT	260	137	+90%
18.7%	10.3%		EBITDA margin	19.7%	13.7%	

- DAG benefited from increased prices and positive market conditions up until the last quarter
- DE (Automotive) and DMM (Building & Construction) were hit hard by the economic crisis

Cash flow & balance sheet highlights


Cash Flow (€ million)	FY 2008	FY 2007
• Cash from operating activities	910	825
• Cash from investing activities	-794	-394
Free cash flow from operations	116	431
• Change in operating working capital	-180	-124
• Capital expenditure	-591	-434
• Acquisitions and disposals	- 93	-34

Balance Sheet (€ million)	Dec 31 2008	Dec 31 2007
• Net debt	1,781	1,338
• Gearing	28%	20%

Q4 actions to manage the crisis

- Positive cash flow in Q4
 - Reduced operating capital
 - (Capex) projects postponed
- Strong financial position
- Credit rating A3 / A- both with stable outlook confirmed
- Successfully issued new bond €500m in March 2009
- Pensions sufficiently funded (no additional cash contribution)
- Set up dedicated coordination office

Debt Maturity Profile (€ m)
Bonds and Private Loans (March 25, 2009)




Successful cash generation: €392m in Q4

Agenda

- Operational performance 2008
- *Vision 2010* update
- Outlook 2009


Focus on Life Sciences and Material Sciences



Exploiting strong market positions and technology platforms

Growth opportunities remain in current markets

Climate and Energy



Health and Wellness



Functionality and Performance




Emerging Economies




DSM is convinced the chosen strategy is the right one

Balanced portfolio in economic downturn

2008 Sales per Cluster



2008 Sales per end market



Nutrition, Pharma and DSM Dyneema relatively unaffected

Cost saving plans underway

- Workforce reduction of about 1000 positions
- Purchasing savings
- Other efficiency improvements

- Capital expenditure focused on future growth projects (e.g. Dyneema)

- Further measures will be implemented as required, but preserve capabilities for when market growth returns

Total savings up to €100m by 2010

Progress partnering & disposals 2008

- DSM has slowed down main disposal process (DSM Agro and DSM Melamine and the ammonia plants, DSM Elastomers, Urea Licensing)
- Progress DSM Anti-Infectives
 - MBO DSM Deretil side chain business
 - Closure of clavulanic business in Sweden
- Citric Acid; Closure of Wuxi site
- Proceed with disposal process for DSM Special Products

Targeted completion within time horizon of *Vision 2010*

Main acquisitions in 2008

- Good progress in acquisitions:
 - Soluol (US) and Polymeric Processes by DSM Resins
 - Polymer Technology Group (US) by DSM Biomedical
 - Valley Research (US) and CMT (Italy) by DSM Food Specialties
- Investments added to our venturing portfolio:
 - Provexis (UK), IQ Therapeutics (NL), The Compliers Group Int (NL)
 - Tianjin Green Bio-Science (China), Accelerated Technologies II (US)
- Partnerships strengthening innovation:
 - Roquette (France)
 - Abengoa and research institutes


Acquisition path will be continued

New milestones achieved in China

- 2008 sales to China US\$ 1.15bn
- Increase of ~20% y-o-y
- Q4'08 sales grew by 2%
- Future growth difficult to predict


- DSM China's top employer for third consecutive year
- New research campus marks start of new DSM era in China
- Contracts signed with NCPC to establish nutrition and anti-infectives joint ventures in China

Sales growth in China (in US\$ m.)



Drop in demand in Q4; US\$ 1.5bn target in 2010

Innovation sales growth towards €1bn in 2010



Sales 2008 €600m, €1bn target in 2010

Commitment to culture change

- Key focus areas:
 - Stronger market and customer focus
 - Accountability as performance drive
 - Inspirational leadership
 - Keen eye on sustainability & more diverse organization
- Supporting initiatives:
 - Cash flow orientation
 - Identifying opportunities



Summary update *Vision 2010*

- Shift to Life Sciences and Materials Sciences continued
- Successful acquisitions achieved
- Disposal program planned within time horizon of *Vision 2010*
- Organic growth 8%; record profitability
- China sales US\$ 1.15bn in 2008, target US\$ 1.5bn in 2010
- Innovation sales € 0.6bn in 2008, target € 1bn in 2010
- Dividend proposal at € 1.20 per share
- Current share buy-back program cancelled
- Progress in sustainability

Good progress but some draw backs due to the economic downturn

Agenda

- Operational performance 2008
- *Vision 2010* update
- Outlook 2009

Nutrition

- Limited impact from recession
- Important changes in Vitamins industry continue:
 - Differentiation based on quality and safety awareness
 - Changing dynamics in China
 - DSM only fully integrated player



Business conditions remain favorable

Pharma

- Limited impact from recession
- DSM Anti-Infectives
 - Good progress with restructuring
- DSM Pharmaceutical Products
 - Loss of some larger custom manufacturing products




Faces challenges

Performance Materials

- Drop in automotive and electronic demand, slowdown in building and construction
- 2009 high uncertainty for DEP and DRS
- DSM Dyneema continues growth
- Bio materials and cost saving solutions offers innovation opportunities

Historic EBIT margin performance




Predictability is difficult

Polymer Intermediates

- Sharp drop in demand
- Lack of clarity for 2009
- Flexibility towards customers and suppliers offer opportunities

Historic EBIT margin performance




Most likely be loss making in 2009

Base Chemicals and Materials

- Steep demand decline in automotive, slowdown in building and construction
- Low clarity for 2009
- Competitors' plant closures and new EPDM technology offer opportunities

Historic EBIT margin performance



Low clarity, price pressure currently in DSM Agro

Earnings guidance

- No quantitative outlook provided for 2009 in view of the uncertain economic conditions

See full text in press release

Conclusions

- Record year
- Difficult fourth quarter, cash prioritized over short term profitability
- Half of portfolio relatively unaffected
- *Vision 2010* is the right strategy; DSM staying the course
- Strong balance sheet and financial flexibility
- Swiftly responded with cost savings program already in December
Further actions to be taken when necessary

Committed to generate cash to secure future profitable growth

Questions & Answers Session

Life Sciences & Materials Sciences

Staying the Course

**Rolf-Dieter Schwalb
CFO Royal DSM**

